In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region.
The frequency and distribution of labelled cells were studied immunohistochemically in 37 squamous cell carcinomas (SCC) of head and neck after in vivo infusion of IdUrd and BrdUrd. Tumours were classified according to their labelling patterns. Low and moderate grade SCC consisted of tumour islands separated by interstitial tissue. In some tumours labelled cells only appeared near the basal layer while in others proliferative cells were evenly distributed within the neoplastic island. In anaplastic carcinomas labelled cells were distributed either randomly or around blood vessels (cord structures). While the basal layer in adjacent normal epithelium contained very few labelled cells (LI = 1.6 +/- 0.2%), the LI of basal cells in tumour islands were much higher than the average LI of the tumour (47.2 +/- 2.8% and 23.8 +/- 1.6%, respectively). In patients who had received cytotoxic therapy up to two months before the biopsy, the LI in the basal layer of normal epithelium was 19.0 +/- 3.5%. In sequential biopsies obtained 1-2 weeks after the infusion of IdUrd and BrdUrd some labelled tumour cells were found in necrotic foci and in pearl structures. Additionally, in six tumours, we found areas of cells labelled with IdUrd alone, even though the IdUrd infusion had been followed by a BrdUrd infusion 1 h later. This is in agreement with the phenomenon of intermittent tumour blood flow described earlier in experimental tumours.
Kotelnikov
V M
VM
Rush Cancer Institute, Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612-3833, USA.
Coon
J S
JS
Taylor
S
S
Hutchinson
J
J
Panje
W
W
Caldarelli
D D
DD
LaFollette
S
S
Preisler
H D
HD
D014408:Biomarkers, Tumor; D001706:Biopsy; D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D004847:Epithelial Cells; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D007065:Idoxuridine; D007984:Leydig Cell Tumor / Q000473:pathology; D009092:Mucous Membrane / Q000473:pathology; D016196:S Phase / Q000502:physiology
D014408:Biomarkers, Tumor; D001973:Bromodeoxyuridine; D007065:Idoxuridine